Sigma Life Science reaches milestone in gene editing
Makes CompoZr ZFNs more affordable and expands Knockout ZFNs to include every gene in mice and rats
Sigma Life Science has released more Knockout ZFNs covering the entire genomes of both mice and rats during the development of CompoZr zinc finger nuclease (ZFN) technology.
The increased capacity of the firm’s new manufacturing facility, together with advances in ZFN design algorithms and production processes, has led to cost reductions in the development and production for both CompoZr Custom and Knockout ZFNs.
This breakthrough in genome editing has allowed Sigma Life Science to extend the range of its Knockout ZFNs and to make ZFN technology more affordable to researchers.
The expansion of the Knockout ZFNs for every mouse and rat gene is in its initial phase, which complements the firm’s existing Knockout ZFNs for the entire human genome.
David Smoller, Sigma Life Science’s chief scientific officer, said CompoZr ZFNs are now available in multiple formats, multiple species and at more accessible pricing.
He added: ‘It is now our objective to continue to drive the development of new applications for CompoZr ZFNs, while maintaining this vital affordability.’